16 September 2026 editorial review · Item
Ustekinumab (IL-12/23 p40 blocker): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Ustekinumab adolescent randomized 12-month signal checked; adult trial remains a test of generalizability. No prevention or T1D approval.
- Registry NCT03941132: ACTIVE_NOT_RECRUITING; updated 2025-02-24; enrollment 66 (ESTIMATED); primary completion 2026-02-01 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: s41591-024-03115-2; 761044s010lbl.pdf.